Search the Newsreel

Abbott (ABT) Lands Exclusive Rights To FDA Approved SimpleScreen In The U.S.

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA approved blood based colorectal cancer screening test. …

Fabtech Tech Standalone June 2026 Net Sales at Rs 49.15 crore, up 63.13% Y-o-Y

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?

AbbVie (NYSE: ABBV), one of the world's largest pharmaceutical companies, is usually considered a blue chip dividend stock rather than a higher-growth one. Yet over the past five years, its stock has rallied 125% and delivered a total return of 170% with reinvested dividends. …

Abbott Laboratories (ABT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Abbott Laboratories (ABT), listing its major shareholders and institutional holdings. It provides a breakdown of the largest individual shareholders like Vanguard and BlackRock, as well as categorizes shareholder types such as investment advisors and pension funds. The …

Fabtech Technologies posts ₹4.21 crore profit in Q1FY27 on margin expansion

UBS Adjusts Price Target on Abbott Laboratories to $125 From $135, Maintains Buy Rating

UBS has revised its price target for Abbott Laboratories (ABT) to $125, down from the previous $135, while reiterating a Buy rating on the stock. This adjustment reflects a moderated outlook but continues to signal confidence in the company's performance. The stock's current performance …

Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

Abbott Laboratories is focusing on continuous glucose monitoring, oncology diagnostics, and advanced cardiovascular treatment as key innovation themes for long-term growth. The company has seen strong sales in these areas, including its FreeStyle Libre, despite facing risks like reimbursement challenges, integration demands from acquisitions, …

Freenome went public for $300 million, then scored a huge victory with colorectal cancer test

Freenome Inc. has received FDA approval for its SimpleScreen CRC, a blood test for early detection of colorectal cancer, which will be marketed by Abbott starting this fall. This marks a significant achievement for the company, following its public offering for $300 million.

FRAUD AND MANIPULATION—N.D. Ill.: Abbott did not commit securities fraud over tainted baby formula

The Northern District of Illinois ruled that Abbott Laboratories did not commit securities fraud regarding its tainted baby formula. This decision indicates that the allegations did not meet the legal threshold for securities fraud. The case was brought against the company concerning the public …

Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth?

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a …

Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth

Abbott Laboratories (ABT) experienced a decline in performance in Q2 2026, primarily due to lowered full-year guidance after the Exact Sciences acquisition, headwinds in its Nutrition and Diagnostics segments, and ongoing litigation concerns related to its preterm infant formula. These issues overshadowed strong organic …

Is Abbott Stock Attractive After Its Earnings and Guidance Update?

Abbott Laboratories (ABT) reported a stronger second quarter with an earnings beat and raised its full-year profit outlook, driven by growth in medical devices and cancer diagnostics. Despite these positive updates and a diversified business model providing support, the stock's valuation offers limited upside …

Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson

This Zacks Investment Ideas feature highlights General Motors, Abbott Laboratories, and Johnson & Johnson, all of which posted strong Q2 earnings and raised their guidance. These guidance upgrades are considered a bullish indicator, often leading to positive share reactions and reflecting improving business fundamentals, …

Al-Babtain Power & Telecommunication Co. Revenue Breakdown – TADAWUL:2320

Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings

Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …

Abbott Laboratories Aktie: 12,51 Milliarden im Quartal

PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records

Schubert Jonckheer & Kolbe LLP is investigating a data breach impacting Abbott Laboratories and its subsidiary Exact Sciences Corporation. An unauthorized third party, allegedly ShinyHunters, accessed legacy cancer diagnostics systems in July 2026, potentially exfiltrating sensitive patient information including names, contact details, dates of …

Abbott Laboratories (ABT) Could Be 14% Undervalued On Mixed Earnings And Growth Focus

Abbott Laboratories (ABT) is considered 14% undervalued despite mixed Q2 2026 earnings, which showed increased sales but lower net income year-over-year. The company's stock has seen short-term gains, rising 13.9% over 30 days, reflecting a reset in investor expectations and a focus on future …

Abbott Laboratories (ABT) Impulsó Sus Ventas, ¿Sigue Infravalorada?

Abbott Laboratories Revenue Breakdown – NYSE:ABT

Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall

A federal judge in Chicago has dismissed a lawsuit against Abbott Laboratories that accused the company of defrauding shareholders regarding its 2022 infant formula recall. The judge stated that despite a lengthy complaint, shareholders failed to adequately present claims against Abbott or individual defendants.

ABT|Abbott Laboratories|Kurs:108.442|Änderung %:+0.632

ABT|Abbott Laboratories|Price:107.810|Chg%:-0.150

Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum

Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …

Abbott Stock And 2 Dividend Ideas For Retirement Income

This article explores three dividend stocks—Abbott Laboratories (ABT), Yü Group (AIM:YU.), and Artesian Resources (ARTN.A)—as potential retirement income sources, especially in light of Social Security reform concerns. It analyzes each company's overview, operations, market cap, and investment considerations, highlighting their strengths and risks for …

Abbott Faces Joint Spinal Cord Stimulator Lawsuit Filed by 17 Patients

Seventeen patients have filed a joint product liability lawsuit against Abbott Laboratories, alleging that its spinal cord stimulator (SCS) systems were defective, failed to alleviate chronic pain, and caused painful neurological complications. The lawsuit claims that Abbott misrepresented the safety and approval status of …

Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating

Daiwa Securities has adjusted its price target for Abbott Laboratories (ABT) to $103 from $92, while maintaining a Neutral rating on the stock. This adjustment comes amidst other analyst revisions for Abbott Laboratories, with several firms raising their price targets and maintaining positive ratings. …

Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026

Abbott Laboratories reported increased sales in Q2 2026 and for the first half of the year, but experienced a significant drop in net income and diluted earnings per share. This performance raises questions about cost pressures and profitability, leading to a focus on cost …

Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over …

Fabtech Technologies to discuss Q1 FY27 results on July 28

Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades

Abbott Laboratories (ABT) stock appears undervalued by roughly 32% according to Discounted Cash Flow (DCF) analysis and a tailored P/E ratio, despite trading at a premium to some industry averages. The valuation considers the company's shift towards higher-margin MedTech and diagnostics, including cancer and …

Patients sue diagnostics company over data breach

A class action lawsuit has been filed against Abbott Laboratories and its subsidiary Exact Sciences by Illinois patients, alleging the companies failed to adequately protect their sensitive data from a ransomware attack. The breach, for which the cybercriminal group ShinyHunters claimed responsibility, reportedly compromised …

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this maker of infant formula, medical devices …

Lobbying Update: $1,150,000 of ABBOTT LABORATORIES lobbying was just disclosed

Abbott Laboratories disclosed $1,150,000 in lobbying expenditures for Q2 2026, covering issues such as healthcare legislation, trade agreements, data privacy, and medical device regulations. The report also details recent insider trading activities, congressional stock trades involving ABT, hedge fund adjustments to their holdings, and …

This Dividend King Could Be One of the Safest Stocks to Own Right Now

A gold crown with sparkling dust by tomertu via Shutterstock Choosing the right dividend stock isn't just about chasing the highest yields. The best dividend stocks are often the ones that quietly raise their payouts year after year while continuing to grow the underlying …

Healthcare giant Abbott probes two cyber incidents amid extortion claims

Abbott Laboratories is investigating two separate cyber incidents, one affecting its Cancer Diagnostics business and another involving its LabCentral customer portal. While Abbott asserts no impact on manufacturing or patient care and denies sensitive customer data exposure through LabCentral, cybercriminal groups ShinyHunters and ShadowByt3$ …